-
EP3868404
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3868404
| EP3868404 - SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 04.03.2022 Database last updated on 28.03.2026 | |
| Former | The application has been published Status updated on 23.07.2021 | Most recent event Tooltip | 21.01.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | For all designated states GENENTECH, INC. 1 DNA Way South San Francisco, CA 94080 / US | [2021/34] | Inventor(s) | 01 /
ENG-WONG, Jennifer c/o Genentech Inc. 1 DNA Way South San Francisco, California 94080 / US | 02 /
KIRSCHBROWN, Whitney c/o Genentech Inc. 1 DNA Way South San Francisco, California 94080 / US | 03 /
KHAN, Tarik c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 04 /
LIN, Jasper c/o Genentech, Inc. 1 DNA Way South San Francisco, California 94080 / US | 05 /
ALAVATTAM, Sreedhara c/o Genentech, Inc. 1 DNA Way South San Francisco, California 94080 / US | 06 /
GARG, Amit c/o Genentech, Inc. 1 DNA Way South San Francisco, California 94080 / US | 07 /
HEESON, Sarah c/o Roche Products Limited Hexagon Place 6 Falcon Way, Shire Park Welwyn Garden City Greater London, AL7 1TW / GB | 08 /
BADOVINAC-CRNJEVIC, Tanja c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 09 /
WURTH, Christine c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2021/34] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2021/34] | Townsend, Carolin F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124 4070 Basel / CH | Application number, filing date | 20191022.1 | 16.01.2018 | [2021/34] | Priority number, date | US201762447359P | 17.01.2017 Original published format: US 201762447359 P | [2021/34] | Previously filed application, date | WO2018US13854 | 16.01.2018 | [2021/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3868404 | Date: | 25.08.2021 | Language: | EN | [2021/34] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 26.07.2021 | Classification | IPC: | A61K39/395, A61K9/00, A61K9/08, A61K38/47, A61K47/18, A61K47/20, A61K47/26, A61K47/42, C07K16/32, A61K39/00, A61P35/00 | [2021/34] | CPC: |
A61K9/0019 (EP,IL,KR,US);
A61K39/395 (IL);
A61K39/39591 (EP,KR,RU,US);
C07K16/32 (EP,CN,IL,KR,RU,US);
A61K45/06 (CN);
A61K31/015 (CN);
A61K38/47 (EP,KR,US);
A61K39/001106 (EP,CN,IL,RU,US);
A61K39/3955 (CN);
A61K39/39558 (KR);
A61K40/4205 (KR);
A61K47/183 (EP,IL,KR,US);
A61K47/20 (EP,KR,US);
A61K47/26 (EP,KR,US);
A61K47/42 (CN);
A61K9/08 (EP,CN,IL,KR,US);
A61P35/00 (EP,CN,IL,KR,RU,US);
C07K16/28 (IL,US);
C07K16/2863 (CN,IL,RU);
C07K16/30 (IL,US);
C07K16/40 (CN);
C12Y302/01035 (EP,IL,US);
A61K2039/505 (EP,CN,IL,US);
A61K2039/507 (EP,CN,IL,US);
A61K2039/54 (EP,IL,US);
A61K2039/545 (EP,IL,US);
A61K2039/585 (EP,IL,KR,US);
A61K2121/00 (KR);
A61K2300/00 (KR);
C07K2317/24 (EP,IL,US);
| C-Set: |
A61K31/015, A61K2300/00 (CN);
A61K39/3955, A61K2300/00 (CN) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/13] |
| Former [2022/14] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | ||
| Former [2021/34] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Validation states | MA | 25.02.2022 | Title | German: | SUBKUTANE HER2-ANTIKÖRPERFORMULIERUNGEN | [2021/34] | English: | SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS | [2021/34] | French: | FORMULATIONS SOUS-CUTANÉES D'ANTICORPS HER2 | [2021/34] | Examination procedure | 06.11.2020 | Loss of particular rights, legal effect: Claims | 13.11.2020 | Despatch of communication of loss of particular rights: Claims {1} | 25.02.2022 | Examination requested [2022/14] | 25.02.2022 | Date on which the examining division has become responsible | 18.03.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 06.01.2025 | Amendment by applicant (claims and/or description) | Parent application(s) Tooltip | EP18713735.1 / EP3570884 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 25.05.2022 | Request for further processing filed | 25.05.2022 | Full payment received (date of receipt of payment) Request granted | 02.06.2022 | Decision despatched | Fees paid | Renewal fee | 14.12.2020 | Renewal fee patent year 03 | 12.01.2021 | Renewal fee patent year 04 | 13.01.2022 | Renewal fee patent year 05 | 11.01.2023 | Renewal fee patent year 06 | 23.01.2024 | Renewal fee patent year 07 | 21.01.2025 | Renewal fee patent year 08 | 21.01.2026 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] US2011044977 (ADLER MICHAEL et al.) | [XYI] HOFFMANN-LA ROCHE: "A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)", 14 April 2016 (2016-04-14), XP002781216, Retrieved from the Internet | [Y] SALIMA HAMIZI ET AL: "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", ONCOTARGETS AND THERAPY, vol. 6, 13 February 2013 (2013-02-13), pages 89 - 94, XP055476980, DOI: 10.2147/OTT.S27733 DOI: http://dx.doi.org/10.2147/OTT.S27733 | [A] JOSE BASELGA ET AL: "Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer", NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, no. 2, 12 January 2012 (2012-01-12), pages 109 - 119, XP055057318, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1113216 DOI: http://dx.doi.org/10.1056/NEJMoa1113216 | Examination | GILLES FREYER ET AL: "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", ONCOTARGETS AND THERAPY, 1 February 2013 (2013-02-01), pages 89, XP055476970, DOI: 10.2147/OTT.S27733 DOI: http://dx.doi.org/10.2147/OTT.S27733 | by applicant | US5821337 | WO9931140 | US2003170234 | US2003147884 | WO0189566 | US2002064785 | US2003134344 | US6573043 | US6905830 | US2003152987 | US2006034842 | US2008102069 | US5677171 | US5720937 | US5720954 | US5725856 | US5770195 | US5772997 | US6165464 | US6387371 | US6399063 | US6015567 | US6333169 | US4968603 | US6054297 | US6407213 | US6639055 | US6719971 | US6800738 | US5648237 | US7018809 | US6267958 | US6695940 | US6821515 | US7060268 | US7682609 | US7371376 | US6127526 | US6333398 | US6797814 | US6339142 | US6417335 | US6489447 | US7074404 | US7531645 | US7846441 | US7892549 | US7129840 | US7344840 | US7468252 | US7674589 | US6949245 | US7485302 | US7498030 | US7501122 | US7537931 | US7618631 | US7862817 | US7041292 | US6627196 | US7371379 | US6632979 | US7097840 | US7575748 | US6984494 | US7279287 | US7811773 | US7993834 | US7435797 | US7850966 | US7485704 | US7807799 | US7560111 | US7879325 | US7449184 | US7700299 | US2010016556 | US2005244929 | US2001014326 | US2003202972 | US2006099201 | US2010158899 | US2011236383 | US2011033460 | US2005063972 | US2006018739 | US2009220492 | US2004037823 | US2005002928 | US2007292419 | US2008187533 | US2005100944 | US2006183150 | US2008050748 | US2010120053 | US2005244417 | US2007026001 | US2008160026 | US2008241146 | US2005208043 | US2005238640 | US2006073143 | US2006193854 | US2006198843 | US2011129464 | US2007184055 | US2007269429 | US2008050373 | US2006083739 | US2009087432 | US2006210561 | US2002035736 | US2002001587 | US2008226659 | US2002090662 | US2006046270 | US2008108096 | US2007166753 | US2008112958 | US2009239236 | US2004008204 | US2009187007 | US2004106161 | US2011117096 | US2004048525 | US2004258685 | US2009148401 | US2011117097 | US2006034840 | US2011064737 | US2005276812 | US2008171040 | US2009202536 | US2006013819 | US2006018899 | US2009285837 | US2006088523 | US2010015157 | US2006121044 | US2008317753 | US2006165702 | US2009081223 | US2006188509 | US2009155259 | US2011165157 | US2006204505 | US2006212956 | US2006275305 | US2007009976 | US2007020261 | US2007037228 | US2010112603 | US2006067930 | US2007224203 | US2008038271 | US2008050385 | US2010285010 | US2010008975 | US2011027190 | US2010298156 | US2009098135 | US2009148435 | US2009202546 | US2009226455 | US2009317387 | US2011044977 | WO2004078140 | WO2006091871 | WO9704801 | US6685940 | US6821151 | WO2006044908 | US8372396 | US9017671 | US9345661 | US8404234 | US5183884 | US5480968 | US7981418 | WO9845479 | US4933294 | WO9105264 | US5401638 | US4816567 | US2002136719 | BASELGA, J. CLIN. ONCOL., vol. 14, 1996, pages 737 - 744 | SLAMON ET AL., N ENGL J MED., vol. 344, no. 11, 2001, pages 783 - 792 | MARTY ET AL., J CLIN ONCOL., vol. 23, no. 19, 2005, pages 4265 - 4274 | HARARIYARDEN, ONCOGENE, vol. 19, 2000, pages 6102 - 14 | YARDENSLIWKOWSKI, NAT REVMOL CELL BIOL, vol. 2, 2001, pages 127 - 37 | SLIWKOWSKI, NAT STRUCT BIOL, vol. 10, 2003, pages 158 - 9 | CHO ET AL., NATURE, vol. 421, 2003, pages 756 - 760 | MALIK ET AL., PRO AM SOC CANCER RES, vol. 44, 2003, pages 176 - 7 | AGUS ET AL., CANCER CELL, vol. 2, 2002, pages 127 - 37 | ALLISON ET AL., PRO AM SOC CLIN ONCOL, vol. 22, 2003, pages 197 | BASELGA ET AL.: "2007 ASCO Annual Meeting Proceedings", J CLIN ONCOL, vol. 25, no. 18S, 20 June 2007 (2007-06-20), pages 1004 | BASELGA ET AL., NENGJMED, vol. 366, no. 2, 2012, pages 109 - 119 | GIANNI ET AL., LANCET ONCOL, vol. 13, no. 1, 2012, pages 25 - 32 | GIANNI ET AL., LANCET ONCOL, vol. 17, no. 6, 2016, pages 791 - 800 | FROST I. G.STERN, R.: "A microtiter-based assay for hyaluronidase activity not requiring specialized reagents", ANAL. BIOCHEMISTRY, vol. 251, 1997, pages 263 - 269, XP002276368, DOI: 10.1006/abio.1997.2262 DOI: http://dx.doi.org/10.1006/abio.1997.2262 | DANILKOVITCH-MIAGKOVA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, no. 8, 2003, pages 4580 - 4585 | PHELPS ET AL., SCIENCE, vol. 240, no. 4860, 1988, pages 1780 - 1782 | FROST, I. G. ET AL.: "Purification, cloning, and expression of human plasma hyaluronidase", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 236, no. 1, 1997, pages 10 - 15, XP002915950, DOI: 10.1006/bbrc.1997.6773 DOI: http://dx.doi.org/10.1006/bbrc.1997.6773 | LALANCETTE ET AL., BIOL. REPROD., vol. 65, no. 2, 2001, pages 628 - 36 | ARMING ET AL., EUR. J. BIOCHEM., vol. 247, no. 3, 1997, pages 810 - 4 | CHERR ET AL., DEV. BIOL., vol. 175, no. 1, 1996, pages 142 - 53 | BYWATERS G. L. ET AL.: "Reconstitution of the dermal barrier to dye spread after Hyaluronidase injection", BR. MED. J., vol. 2, no. 4741, 1951, pages 1178 - 1183 | BOOKBINDER L. H. ET AL.: "A recombinant human enzyme for enhanced interstitial transport of therapeutics", J. CONTROL. RELEASE, vol. 114, 2006, pages 230 - 241, XP024957594, DOI: 10.1016/j.jconrel.2006.05.027 DOI: http://dx.doi.org/10.1016/j.jconrel.2006.05.027 | FROST, G. I.: "Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration", EXPERT OPINION ON DRUG DELIVERY, vol. 4, 2007, pages 427 - 440, XP008177677, DOI: 10.1517/17425247.4.4.427 DOI: http://dx.doi.org/10.1517/17425247.4.4.427 | DURAN-REYNOLDS F.: "A spreading factor in certain snake venoms and its relation to their mode of action", CR SOC BIOL PARIS, 1938, pages 69 - 81 | CHAIN E.: "A mucolytic enzyme in testes extracts", NATURE, 1939, pages 977 - 978 | WEISSMANN, B.: "The transglycosylative action of testicular hyaluronidase", J. BIOL. CHEM., vol. 216, 1955, pages 783 - 94 | TAMMI, R.SAAMANEN, A. M.MAIBACH, H. I.TAMMI M.: "Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture", J. INVEST. DERMATOL., vol. 97, 1991, pages 126 - 130 | LAURENT, U. B. G.DAHL, L. B.REED, R. K.: "Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver", EXP. PHYSIOL., vol. 76, 1991, pages 695 - 703 | LAURENT, T. C.FRASER, J. R. E.: "Degradation of Bioactive Substances: Physiology and Pathophysiology", 1991, MARCEL DEKKER, INC., article "Peptide and Protein", pages: 247 - 301 | HARRIS, E. N. ET AL.: "Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE", J. BIOL. CHEM., vol. 279, 2004, pages 36201 - 36209 | JONES, A., ADV. DRUG DELIVERY REV., vol. 10, 1993, pages 29 - 90 | SEMBA ET AL., PNAS (USA), vol. 82, 1985, pages 6497 - 6501 | YAMAMOTO ET AL., NATURE, vol. 321, 1986, pages 522 - 525 | "Genebank", Database accession no. X03363 | GARRETT ET AL., MOL. CELL, vol. 11, 2003, pages 495 - 505 | FRANKLIN ET AL., CANCER CELL, vol. 5, 2004, pages 317 - 328 | PLOWMAN ET AL., PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 1746 - 1750 | KRAUS ET AL., PNAS (USA), vol. 86, 1989, pages 9193 - 9197 | SLIWKOWSKI ET AL., J. BIOL. CHEM., vol. 269, no. 20, 1994, pages 14661 - 14665 | JOHNS ET AL., J. BIOL. CHEM., vol. 279, no. 29, 2004, pages 30375 - 30384 | RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329 | PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596 | STANCOVSKI ET AL., PNAS (USA, vol. 88, 1991, pages 8691 - 8695 | CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 | MARKS ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 779 - 783 | BARBAS ET AL., PROC NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813 | SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155 | JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 2004 | HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896 | TANNER ET AL., AM. J. PATHOL., vol. 157, no. 5, 2000, pages 1467 - 1472 | BELLA ET AL., J. CLIN. ONCOL., vol. 26, 20 May 2008 (2008-05-20) | SIAS ET AL., J. IMMUNOL. METHODS, vol. 132, 1990, pages 73 - 80 | BOSE ET AL., CANCER DISCOV, vol. 3, 2013, pages 1 - 14 | STEPHENS ET AL., NATURE, vol. 431, 2004, pages 525 - 6 | SHIGEMATSU ET AL., CANCER RES, vol. 65, 2005, pages 1642 - 6 | BUTTITTA ET AL., INT J CANCER, vol. 119, 2006, pages 2586 - 91 | LI ET AL., ONCOGENE, vol. 27, 2008, pages 4702 - 11 | SEQUIST ET AL., J CLIN ONCOL, vol. 28, 2010, pages 3076 - 83 | ARCILA ET AL., CLIN CANCER RES, vol. 18, 2012, pages 4910 - 8 | GREULICH ET AL., PROC NATL ACAD SCI U S A, vol. 109, 2012, pages 14476 - 81 | HERTER-SPRIE ET AL., FRONT ONCOL, vol. 3, 2013, pages 1 - 10 | "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY | AGNEW, CHEMLNTL. ED. ENGL., vol. 33, 1994, pages 183 - 186 | KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 | KABAT ET AL.: "Sequences ofProteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH | CARTER ET AL., PNAS (USA, vol. 89, 1992, pages 4285 - 4289 | HARRIS ET AL., J. CHROMATOGRAPHY, vol. B 752, 2001, pages 233 - 245 | CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 75971-58-7 | HUDZIAK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7159 - 7163 | SLAMON ET AL., SCIENCE, vol. 244, 1989, pages 707 - 712 | SLAMON ET AL., SCIENCE, vol. 235, 1987, pages 177 - 182 | "Remington's Pharmaceutical Sciences", 1980 | GARG ET AL., CANCER CHEMOTHER PHARMACOL, vol. 74, 2014, pages 819 - 829 | GARG ET AL., CANCER CHEMOTHER PHARMACOL., vol. 74, 2014, pages 819 - 829 |